Sandbox carlos: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 4: Line 4:
::* '''1.Primary pulmonary infection in patients low risk persistence/complication:''' Antifungal treatment not generally recommended. Treat fever weight loss and/or fatigue.
::* '''1.Primary pulmonary infection in patients low risk persistence/complication:''' Antifungal treatment not generally recommended. Treat fever weight loss and/or fatigue.


::* 1.1 Primary pulmonary infection in patients with increased risk of complications or dissemination:
::* '''1.1 Primary pulmonary infection in patients with increased risk of complications or dissemination:'''
:::*Mild to moderate severity.Preferred regimen: [[Itraconazole]] solution 200 mg po or IV bid {{OR}} [[Fluconazole]] 400 mg po q24h for 3–12 mo
:::* Mild to moderate severity.Preferred regimen: [[Itraconazole]] solution 200 mg po or IV bid {{OR}} [[Fluconazole]] 400 mg po q24h for 3–12 mo
 
:::* Locally severe or disseminated disease: Amphotericine B 0.6–1 mg/kg per day x 7 days then 0.8 mg/kg every other day or liposomal ampho B 3-5 mg/kg/d IV or ABLC 5 mg/kg/d IV, until clinical improvement (usually several wks or longer in disseminated disease), followed by itra or flu for at least 1 year.
::* Locally severe or disseminated disease:
:::Note (1) Some use combination of Ampho B & Flu for progressive severe disease; controlled series lacking.
:::Ampho B 0.6–1 mg/kg per day x 7 days then 0.8 mg/kg every other day or liposomal ampho B 3-5 mg/kg/d IV or ABLC 5 mg/kg/d IV, until clinical improvement (usually several wks or longer in disseminated disease), followed by itra or flu for at least 1 year.
:::Note (2) Consultation with specialist recommended: surgery may be required.
:::* Some use combination of Ampho B & Flu for progressive severe disease; controlled series lacking.
::Note: Consultation with specialist recommended: surgery may be required.


::* Meningitis:
::* Meningitis:

Revision as of 18:19, 21 July 2015


  • 1.Primary pulmonary infection in patients low risk persistence/complication: Antifungal treatment not generally recommended. Treat fever weight loss and/or fatigue.
  • 1.1 Primary pulmonary infection in patients with increased risk of complications or dissemination:
  • Mild to moderate severity.Preferred regimen: Itraconazole solution 200 mg po or IV bid Template:OR Fluconazole 400 mg po q24h for 3–12 mo
  • Locally severe or disseminated disease: Amphotericine B 0.6–1 mg/kg per day x 7 days then 0.8 mg/kg every other day or liposomal ampho B 3-5 mg/kg/d IV or ABLC 5 mg/kg/d IV, until clinical improvement (usually several wks or longer in disseminated disease), followed by itra or flu for at least 1 year.
Note (1) Some use combination of Ampho B & Flu for progressive severe disease; controlled series lacking.
Note (2) Consultation with specialist recommended: surgery may be required.
  • Meningitis:
Adult:
  • Preferred regimen: Fluconazole 400–1,000 mg po q24h indefinitely
  • Alternative regimen: Ampho B IV as for pulmonary (above) + 0.1–0.3 mg daily intrathecal (intraventricular) via reservoir device. OR itra 400–800 mg q24h OR voriconazole
Some use combination of Ampho B & Flu for progressive severe disease; controlled series lacking.
  • Child
  • Preferred regimen: Fluconazole (po) (Pediatric dose not established, 6 mg per kg q24h used)
  • Alternative regimen: Ampho B IV as for pulmonary (above) + 0.1–0.3 mg daily intrathecal (intraventricular) via reservoir device. OR itra 400–800 mg q24h OR voriconazole
==References==